UCB SA
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About UCB SA
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).
/ 
Others were interested in
See all stocksFrequently asked questions
To buy UCB SA stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for UCB SA by name or ticker, choose the number of shares, and place your order.
The ticker symbol for UCB SA is UCB:xbru. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
UCB SA has its primary listing on Euronext Brussels. You can trade UCB SA with a Saxo account, alongside thousands of other stocks worldwide.
Yes, UCB SA is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include UCB SA as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like UCB SA.